JG
ACOR

Joel Greenblatt’s Acorda Therapeutics ACOR Stock Holding History

Joel Greenblatt’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-202
Closed -$377K – 1256
2018
Q4 		$377K Sell
202
-69
-25% -$150K 0.01% 818
2018
Q3 		$639K Sell
271
-87
-24% -$269K 0.01% 694
2018
Q2 		$1.23M Sell
358
-67
-16% -$205K 0.02% 556
2018
Q1 		$1.21M Buy
425
+59
+16% +$177K 0.02% 580
2017
Q4 		$943K Sell
366
-915
-71% -$2.6M 0.01% 603
2017
Q3 		$3.64M Buy
1,281
+584
+84% +$1.54M 0.05% 424
2017
Q2 		$1.65M Sell
697
-382
-35% -$757K 0.02% 558
2017
Q1 		$2.72M Sell
1,079
-237
-18% -$682K 0.03% 502
2016
Q4 		$2.97M Buy
1,316
+609
+86% +$1.45M 0.04% 458
2016
Q3 		$1.77M Buy
707
+131
+23% +$391K 0.02% 517
2016
Q2 		$1.76M Buy
576
+338
+142% +$1.1M 0.02% 539
2016
Q1 		$754K Buy
+238
New +$988K 0.01% 694
2015
Q1 		– Sell
-1,347
Closed -$6.61M – 1048
2014
Q4 		$6.61M Buy
1,347
+92
+7% +$395K 0.05% 383
2014
Q3 		$5.1M Buy
1,255
+828
+194% +$3.11M 0.05% 397
2014
Q2 		$1.73M Buy
+427
New +$1.74M 0.02% 562

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Joel Greenblatt's ACOR Position: Q1 2019 in Review

Joel Greenblatt sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 202 shares — an estimated $377K sold.

Joel Greenblatt first reported a position in ACOR in Q2 2014 and held it in 15 quarters. The position peaked at $6.61M in Q4 2014. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

  • Joel Greenblatt reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Joel Greenblatt sold 202 Acorda Therapeutics shares in Q1 2019, an estimated $377K.
  • Joel Greenblatt first reported a position in Acorda Therapeutics in Q2 2014 and held it in 15 quarters.
  • Joel Greenblatt's Acorda Therapeutics position peaked at $6.61M in Q4 2014.
  • 184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on Gotham Asset Management's 13F filing for Q1 2019, filed 15 May 2019.